FAS and systemic lupus erythematosus: Using a combination treatment of L-4F and pravastatin, we assessed the therapeutic effects of both drug types in the apoE-/-Fas-/- murine model of accelerated atherosclerosis in lupus and identified potential biomarkers of disease activity for possible future applications in the treatment and monitoring of atherosclerosis in SLE.